Cogent Biosciences, Inc. (COGT): Price and Financial Metrics


Cogent Biosciences, Inc. (COGT): $4.73

0.17 (+3.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add COGT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

COGT Stock Price Chart Interactive Chart >

Price chart for COGT

COGT Price/Volume Stats

Current price $4.73 52-week high $11.06
Prev. close $4.56 52-week low $3.79
Day low $4.55 Volume 253,200
Day high $4.81 Avg. volume 259,025
50-day MA $6.80 Dividend yield N/A
200-day MA $7.75 Market Cap 216.72M

Cogent Biosciences, Inc. (COGT) Company Bio


Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ‘bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


COGT Latest News Stream


Event/Time News Detail
Loading, please wait...

COGT Latest Social Stream


Loading social stream, please wait...

View Full COGT Social Stream

Latest COGT News From Around the Web

Below are the latest news stories about Cogent Biosciences Inc that investors may wish to consider to help them evaluate COGT as an investment opportunity.

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | February 1, 2022

Analysts’ Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma (ALBO – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Albireo Pharma (ALBO) Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma today and set a price target of $84.00. The company's shares closed last Wednesday at $24.31. According to TipRanks.

Brian Anderson on TipRanks | January 6, 2022

Cogent Biosciences Provides 2022 Corporate Guidance

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided 2021 year-end updates and corporate guidance for 2022.

Yahoo | January 5, 2022

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President will participate in a fireside chat and one-on-one investor meetings during the Piper Sandler 33rd Annual Healthcare Conference, taking place virtually November 29 – December 2, 2021.

Yahoo | November 22, 2021

Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the third quarter ended September 30, 2021 and provided corporate updates.

Yahoo | November 10, 2021

Read More 'COGT' Stories Here

COGT Price Returns

1-mo -40.73%
3-mo N/A
6-mo -46.73%
1-year -44.42%
3-year N/A
5-year N/A
YTD -44.87%
2021 -23.60%
2020 289.82%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6452 seconds.